Featured Research

from universities, journals, and other organizations

New ALS drug headed for phase II trial

Date:
October 25, 2013
Source:
Houston Methodist
Summary:
Researchers will soon begin phase IIa clinical trials of TDI-132, a drug that in animal models has shown promise in reducing the inflammation associated with Amyotrophic Lateral Sclerosis.

Researchers at Houston Methodist Neurological Institute and elsewhere will soon begin phase IIa clinical trials of TDI-132, a drug that in animal models has shown promise in reducing the inflammation associated with Amyotrophic Lateral Sclerosis, also known as ALS or Lou Gehrig's Disease.

The purpose of the phase IIa trial is to determine the safety and tolerability of TDI-132 in ALS patients. Individuals in the research group will receive .5 mg of TDI-132 each day for four weeks.

Not all ALS patients are eligible to participate. For eligibility requirements, please visit http://www.als.net/TDI-132.

"Our primary goal in this trial is to determine the safety of fingolimod in a small trial at four centers in the U.S., including our own MDA/ALS Center at Methodist," said Houston Methodist Neurological Institute Director Stanley Appel, M.D. "Prior studies in our animal model as well as in ALS patients indicate the potential therapeutic value of increasing protective T cells, and fingolimod -- an FDA-approved medication with significant benefit for Multiple Sclerosis patients -- may provide similar benefit for our ALS patients, and thus merits initial determination of safety."

ALS Clinical Research Division Director Ericka Simpson, M.D., is the site principal investigator of the study.

TDI-132 is also known as fingolimod, or by its commercial name, Gilenya, a drug originally developed by Novartis International to treat multiple sclerosis. Preclinical studies have shown TDI-132 can decrease the number of immune cells, keeping cells in lymph nodes from entering general circulation. These studies also indicate that decreases in the number of these cells can protect against inflammation and the worsening of symptoms.

The phase IIa trial is being funded by the ALS Therapy Development Institute (ALS TDI), a Cambridge, Mass.-based non-profit biotech.

"Seeing TDI-132 enter into clinical trial for ALS gives me hope that people living with ALS may soon be able to fight back," said Augie Nieto, an ALS patient and chair of the board at ALS TDI.


Story Source:

The above story is based on materials provided by Houston Methodist. Note: Materials may be edited for content and length.


Cite This Page:

Houston Methodist. "New ALS drug headed for phase II trial." ScienceDaily. ScienceDaily, 25 October 2013. <www.sciencedaily.com/releases/2013/10/131025135257.htm>.
Houston Methodist. (2013, October 25). New ALS drug headed for phase II trial. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2013/10/131025135257.htm
Houston Methodist. "New ALS drug headed for phase II trial." ScienceDaily. www.sciencedaily.com/releases/2013/10/131025135257.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins